## **ELI LILLY AND COMPANY**

ISIN: US5324571083 WKN: 532457108 Asset Class: Stock

Company

Lilly

2024/04/26 22:00:02

**Price 733.51** USD

Difference

nce 2 1.19%(8.64) 700.00 600.00 500.00 400.00

05.2023 07.2023 09.2023 11.2023 01.2024 03.2024

**Contact Details** 

ELI LILLY & CO. Tel: +1-317-276-2000

- Fax: +

Lilly Corporate Center

Web: http://www.lilly.com

46285 Indianapolis E-mail:

communications\_corporate@lilly.com

**Company Profile** 

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

# Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	20:	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	25,727,000,000		18,034,500,000		18,452,400,000	
Common stock capital		593,600,000		594,100,000		596,300,000
Fixed assets	38,279,300,000		31,455,300,000		30,353,600,000	
Equity capital of a company		10,863,700,000		10,775,400,000		9,154,800,000
Cash and cash equivalents	2,818,600,000		2,067,000,000		3,818,500,000	
Accrued liabilities		1,438,800,000		1,305,100,000		1,954,100,000
Other assets	-		-		-	
Current liabilities		27,293,200,000		17,138,200,000		15,052,700,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		25,849,400,000		21,576,200,000		24,598,500,000
Different income		-		-		-
Other liabilities		6,089,800,000		5,446,300,000		5,564,300,000
Total assets	64,006,300,000	64,006,300,000	49,489,800,000	49,489,800,000	48,806,000,000	48,806,000,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	43,000	39,000	35,000
Equity ratio	17.12%	22.03%	19.12%
Debt-equity ratio	484.24%	353.99%	423.09%

#### **Others**

	2023	2022	2021
Tax Expense Rate	20.05%	8.25%	9.32%

# **ELI LILLY AND COMPANY**

ISIN: **US5324571083** WKN: **532457108** Asset Class: **Stock** 

Income statement			
	2023	2022	2021
Turnover	34,124,100,000	28,541,400,000	28,318,400,000
Net income	5,240,400,000	6,244,800,000	5,581,700,000
EBIT	6,417,804,740	6,612,481,920	6,046,768,540
Operating income before taxes	6,554,600,000	6,806,400,000	6,155,500,000
Cash Flow	4,240,100,000	7,084,400,000	7,260,700,000
Net interest income	-312,300,000	-268,800,000	-314,400,000
Research and development expenses	9,313,400,000	7,190,800,000	7,025,900,000
Income taxes	1,314,200,000	561,600,000	573,800,000
Result from investments in subsidaries, associates and other	0	-	-
Revenues per employee	741,683	683,969	756,182

## **Board of Directors**

Members of Management Board		
Katherine Baicker	Member of Board of Directors	
Marschall Runge	Member of Board of Directors	
Mary Lynne Hedley	Member of Board of Directors	
William Kaelin	Member of Board of Directors	
Gabrielle Greene-Sulzberger	Member of Board of Directors	
Jamere Jackson	Member of Board of Directors	
Jon Fyrwald	Member of Board of Directors	
Juan Luciano	Member of Board of Directors	
Karen Walker	Member of Board of Directors	
Kimberly Johnson	Member of Board of Directors	
Ralph Alvarez	Member of Board of Directors	
David Ricks	Chairman of Managing Board	
Alonzo Weems	Member of Executive Committee	
Anat Ashkenazi	Member of Executive Committee	
Anat Hakim	Member of Executive Committee	
Anne E. White	Member of Executive Committee	
Daniel M. Skovronsky	Member of Executive Committee	
Diogo Rau	Member of Executive Committee	
Edgardo Hernandez	Member of Executive Committee	
Eric Dozier	Member of Executive Committee	
Ilya Yuffa	Member of Executive Committee	
Jacob Van Naarden	Member of Executive Committee	
Johna L. Norton	Member of Executive Committee	
Patrik Jonsson	Member of Executive Committee	